US Pharma MarketingViridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blo | A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster market. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Fierce 50 Special Report…
A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster market.
Source: FierceBiotech